Infinity presents new preclinical data for PI3K-gamma inhibitor, IPI-549
18 April 2016 | By Victoria White, Digital Content Producer
IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma)...